Chas P. Smith & Associates (CPS)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $426K | Buy |
7,023
+1,322
| +23% | +$77.1K | 0.02% | 111 |
|
|
2025
Q4 | $308K | Buy |
5,701
+1,160
| +26% | +$55.8K | 0.02% | 143 |
|
|
2025
Q3 | $205K | Sell |
4,541
-1,913
| -30% | -$89.3K | 0.02% | 124 |
|
|
2025
Q2 | $299K | Sell |
6,454
-420
| -6% | -$20.6K | 0.02% | 139 |
|
|
2025
Q1 | $419K | Sell |
6,874
-437
| -6% | -$25.5K | 0.02% | 115 |
|
|
2024
Q4 | $413K | Sell |
7,311
-2,570
| -26% | -$144K | 0.02% | 115 |
|
|
2024
Q3 | $511K | Sell |
9,881
-1
| -0% | -$47 | 0.03% | 97 |
|
|
2024
Q2 | $410K | Sell |
9,882
-73
| -0.7% | -$3.27K | 0.02% | 104 |
|
|
2024
Q1 | $540K | Buy |
9,955
+2,886
| +41% | +$147K | 0.03% | 85 |
|
|
2023
Q4 | $363K | Buy |
7,069
+1,315
| +23% | +$69K | 0.02% | 93 |
|
|
2023
Q3 | $334K | Sell |
5,754
-2,860
| -33% | -$175K | 0.02% | 90 |
|
|
2023
Q2 | $551K | Buy |
8,614
+745
| +9% | +$50K | 0.04% | 71 |
|
|
2023
Q1 | $545K | Sell |
7,869
-907
| -10% | -$64K | 0.04% | 68 |
|
|
2022
Q4 | $631K | Buy |
8,776
+101
| +1% | +$7.62K | 0.04% | 65 |
|
|
2022
Q3 | $617K | Buy |
8,675
+3,716
| +75% | +$270K | 0.05% | 59 |
|
|
2022
Q2 | $382K | Sell |
4,959
-19
| -0.4% | -$1.45K | 0.03% | 83 |
|
|
2022
Q1 | $364K | Sell |
4,978
-72
| -1% | -$4.83K | 0.03% | 82 |
|
|
2021
Q4 | $315K | Buy |
5,050
+79
| +2% | +$4.63K | 0.02% | 104 |
|
|
2021
Q3 | $294K | Sell |
4,971
-60
| -1% | -$3.95K | 0.02% | 102 |
|
|
2021
Q2 | $336K | Sell |
5,031
-27
| -0.5% | -$1.76K | 0.03% | 96 |
|
|
2021
Q1 | $319K | Hold |
5,058
| – | – | 0.03% | 85 |
|
|
2020
Q4 | $314K | Sell |
5,058
-25
| -0.5% | -$1.54K | 0.03% | 80 |
|
|
2020
Q3 | $306K | Sell |
5,083
-245
| -5% | -$14.7K | 0.03% | 73 |
|
|
2020
Q2 | $313K | Hold |
5,328
| – | – | 0.04% | 72 |
|
|
2020
Q1 | $297K | Buy |
5,328
+198
| +4% | +$12.1K | 0.04% | 74 |
|
|
2019
Q4 | $329K | Hold |
5,130
| – | – | 0.04% | 80 |
|
|
2019
Q3 | $260K | Hold |
5,130
| – | – | 0.03% | 85 |
|
|
2019
Q2 | $233K | Sell |
5,130
-606
| -11% | -$28.2K | 0.03% | 89 |
|
|
2019
Q1 | $274K | Hold |
5,736
| – | – | 0.03% | 83 |
|
|
2018
Q4 | $298K | Sell |
5,736
-100
| -2% | -$5.37K | 0.04% | 82 |
|
|
2018
Q3 | $362K | Hold |
5,836
| – | – | 0.04% | 77 |
|
|
2018
Q2 | $323K | Sell |
5,836
-135
| -2% | -$7.29K | 0.04% | 78 |
|
|
2018
Q1 | $378K | Sell |
5,971
-980
| -14% | -$63K | 0.05% | 74 |
|
|
2017
Q4 | $426K | Hold |
6,951
| – | – | 0.06% | 72 |
|
|
2017
Q3 | $443K | Sell |
6,951
-1,193
| -15% | -$69.7K | 0.06% | 63 |
|
|
2017
Q2 | $454K | Sell |
8,144
-100
| -1% | -$5.44K | 0.07% | 61 |
|
|
2017
Q1 | $448K | Sell |
8,244
-539
| -6% | -$29.6K | 0.07% | 66 |
|
|
2016
Q4 | $513K | Buy |
8,783
+115
| +1% | +$6.29K | 0.08% | 62 |
|
|
2016
Q3 | $467K | Sell |
8,668
-434
| -5% | -$27.9K | 0.08% | 63 |
|
|
2016
Q2 | $669K | Sell |
9,102
-2,850
| -24% | -$201K | 0.11% | 57 |
|
|
2016
Q1 | $763K | Buy |
11,952
+2,250
| +23% | +$142K | 0.13% | 58 |
|
|
2015
Q4 | $667K | Sell |
9,702
-1,200
| -11% | -$79.3K | 0.12% | 57 |
|
|
2015
Q3 | $645K | Sell |
10,902
-25
| -0.2% | -$1.59K | 0.12% | 55 |
|
|
2015
Q2 | $727K | Sell |
10,927
-297
| -3% | -$19.6K | 0.13% | 57 |
|
|
2015
Q1 | $724K | Sell |
11,224
-400
| -3% | -$25K | 0.13% | 58 |
|
|
2014
Q4 | $686K | Hold |
11,624
| – | – | 0.12% | 57 |
|
|
2014
Q3 | $595K | Buy |
11,624
+50
| +0.4% | +$2.5K | 0.12% | 57 |
|
|
2014
Q2 | $561K | Sell |
11,574
-19,743
| -63% | -$973K | 0.11% | 65 |
|
|
2014
Q1 | $1.63M | Hold |
31,317
| – | – | 0.12% | 58 |
|
|
2013
Q4 | $1.66M | Buy |
31,317
+20,878
| +200% | +$1.06M | 0.13% | 63 |
|
|
2013
Q3 | $483K | Sell |
10,439
-800
| -7% | -$35.1K | 0.12% | 57 |
|
|
2013
Q2 | $502K | Buy |
+11,239
| New | +$488K | 0.13% | 56 |
|
Other funds holding BMY
Chas P. Smith & Associates (CPS)'s BMY Position: Q1 2026 in Review
Chas P. Smith & Associates (CPS) increased its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, buying an estimated $77.1K and bringing the position to 7,023 shares worth $426K. The position accounts for 0.02% of the portfolio, ranked #111.
Chas P. Smith & Associates (CPS) first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.66M in Q4 2013. 2,537 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Chas P. Smith & Associates (CPS) held 7,023 shares of Bristol-Myers Squibb worth $426K as of Q1 2026.
- Chas P. Smith & Associates (CPS) bought 1,322 Bristol-Myers Squibb shares in Q1 2026, an estimated $77.1K.
- Bristol-Myers Squibb made up 0.02% of Chas P. Smith & Associates (CPS)'s portfolio in Q1 2026, its #111 holding.
- Chas P. Smith & Associates (CPS) first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Chas P. Smith & Associates (CPS)'s Bristol-Myers Squibb position peaked at $1.66M in Q4 2013.
- 2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Chas P. Smith & Associates (CPS)'s 13F filing for Q1 2026, filed 12 May 2026.